ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1309 • 2013 ACR/ARHP Annual Meeting

    Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis

    Lillian J. Barra1, Janet E. Pope2, Boulos Haraoui3, Carol A. Hitchon4, J. Carter Thorne5, Edward C. Keystone6,7, Diane Tin8, Gilles Boire9 and Vivian P. Bykerk10, 1Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 2Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 3Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 4Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 5Southlake Regional Health Centre, Newmarket, ON, Canada, 6Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 7Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, 8The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 9Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 10Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY

    Background/Purpose: Rheumatoid Factor (RF) and anti-Cyclic Citrullinated Peptide (anti-CCP) are believed to be associated with more severe clinical outcomes; however, studies in Early Inflammatory Arthritis…
  • Abstract Number: 1310 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of The Japanese Patients With Rheumatoid Arthritis (RA) Of Rapid Radiographic Progression (RRP) Treated With Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) In Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (an interim report of Apple Survey)

    Akitomo Okada1, Atsushi Kawakami2, Takaaki Fukuda3, Toshihiko Hidaka4, Tomonori Ishii5, Yukitaka Ueki6, Takao Kodera7, Munetoshi Nakashima1, Yuichi Takahashi8, Seiyo Honda9, Yoshiro Horai2, Tomohiro Koga10, Mami Tamai11, Kiyoshi Aoyagi12, Ryu Watanabe5, Hiroshi Okuno13 and Katsumi Eguchi14, 1Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, 4Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, 5Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 6Sasebo Chuo Hospital, Sasebo, Japan, 7Tohoku Kosei Nenkin Hospital, Sendai, Japan, 8Yu Family Clinic, Sendai, Japan, 9Kurume University School of Medicene, Kurume, Japan, 10Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 11Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, 12Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 13Tohoku University Hospital, Sendai, Japan, 14Sasebo City General Hospital, Sasebo, Nagasaki, Japan

    Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) are known to inhibit radiographic progression in patients with rheumatoid arthritis (RA). However, there has been few epidemiological report…
  • Abstract Number: 1311 • 2013 ACR/ARHP Annual Meeting

    Aiming Simple Disease Activity Score Remission At One Year Leads To Better 3-Year Radiographic and Functional Outcomes Than aiming low Disease activity in Early Rheumatoid Arthritis Patients Treated In Routine Practice. Data From Espoir Cohort

    Adeline Ruyssen-Witrand1, Gregory Guernec2, Delphine Nigon3, Gabriel Tobon4, Bénédicte Jamard5, Anne-Christine Rat6, Olivier Vittecoq7, Alain G. Cantagrel8 and Arnaud L. Constantin1, 1Rheumatology, Purpan University Hospital, Toulouse, France, 2UMR 1027, Inserm, Toulouse, France, 3Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, 4Unit of immunology, Brest, France, 5Toulouse University Hospital, Toulouse, France, 6Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, 7Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, 8Centre Hospitalier Universitaire de Toulouse, Toulouse, France

    Background/Purpose: The ultimate goal of Disease Modifying Anti-Rheumatic Drugs (DMARDs) treatment in early rheumatoid arthritis (RA) is to achieve remission in order to prevent structural…
  • Abstract Number: 1312 • 2013 ACR/ARHP Annual Meeting

    A Multi-Biomarker Disease Activity Score Correlates With Radiographic Progression In Early Rheumatoid Arthritis: Results From a Randomized  Trial

    Karen Hambardzumyan1, Rebecca Bolce2, Scott E. Cruickshank3, Eric H. Sasso2, David Chernoff2, Kristina Forslind4, Saedis Saevarsdottir5, Ingemar F. Petersson6, Pierre Geborek7, Sofia Ernestam8 and Ronald F van Vollenhoven9, 1ClinTRID, the Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3Scott E. Cruickshank and Associates, Inc., Santa Barbara, CA, 4Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, 5Karolinska Institutet, Stockholm, Sweden, 6Lund University, Lund, Sweden, 7Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 8Huddinge Hospital, Karolinska University Hospital, Huddinge, Sweden, 9ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: In early rheumatoid arthritis (eRA), predictors of radiographic damage would be useful for optimal targeting of therapy.  It has been suggested that combining various…
  • Abstract Number: 1313 • 2013 ACR/ARHP Annual Meeting

    Tobacco Exposure Is Associated With Radiographic Damage In Hispanic and African American Rheumatoid Arthritis Patients

    Rodolfo Perez Alamino1, Luis R. Espinoza2, Gail S. Kerr3, Christopher Swearingen4, Chunqiao Luo5, Yusuf Yazici6, Yvonne R. S. Sherrer7, Edward L. Treadwell8, Angelia D. Mosley-Williams9, Sharon Dowell10, Ignacio Garcia-Valladares11, Theresa Lawrence-Ford12, Adrian Godoy10, Akgun Ince13 and Cindy Flower14, 1Rheumatology, Lousiana State University and LSU Medical Center, New Orleans, LA, 2Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, 3Rheumatology, Washington DC VAMC and Georgetown University and Howard University Hospital, Washington, DC, 4Pediatrics and Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, 5Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, 6New York University Hospital for Joint Diseases, New York, NY, 7Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, 8Dept Medicine Div of Rheum, East Carolina University, Greenville, NC, 9John Dingell VAMC, Detroit, MI, 10Division of Rheumatology, Howard University, Washington, DC, 11Rheumatology, Guadalajara, Guadalajara, Mexico, 12North Georgia Rheumatology Group, PC, Lawrenceville, GA, 13Arthitis Consultants Inc, Saint Louis University, St. Louis, MO, 14Medicine, University of the West Indies, Bridgetown, Barbados

    Background/Purpose: Although the etiology of rheumatoid arthritis (RA) is unknown, there are reported interactions of genetic and environmental factors. Tobacco exposure is a well-documented risk…
  • Abstract Number: 1314 • 2013 ACR/ARHP Annual Meeting

    Synovial Ectopic Lymphoneogenesis Predicts Clinical Response To Certolizumab Pegol In Patients With Rheumatoid Arthritis

    Maria Di Cicco1, Stephen Kelly1, Frances Humby2, Nora Ng1, Sabrina Dadoun3, Rebecca Hands2, Vidalba Rocher2, Alessandra Nerviani1, Michele Bombardieri2 and Costantino Pitzalis4, 1William Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, 2Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 3APHP, Pitié-Salpêtrière University Hospital, Paris, France, 4Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom

    Background/Purpose: Predicting response to anti-TNF alpha inhibitors (TNFi) in rheumatoid arthritis (RA) patients is challenging. Therefore there is a high need for identification of biomarkers…
  • Abstract Number: 1279 • 2013 ACR/ARHP Annual Meeting

    Anti-IL-6 Receptor Antibody Is Effective In Arthritis Regardless Of Obesity In Mouse Model

    Miho Suzuki, Hiroto Yoshida and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan

    Background/Purpose: Compared with non-obese patients, obese patients with rheumatoid arthritis (RA) reportedly experience worsening of symptoms [Arthritis Care Res (Hoboken). 2013; 65: 78-87] and do…
  • Abstract Number: 1293 • 2013 ACR/ARHP Annual Meeting

    Serum Matrix Metalloproteinase 13 As a Translational Marker For Efficacy Of Anti-Arthritic Treatments In Rat Collagen Induced Arthritis and Mouse Model Of Lipopolysaccharide-Induced Bone Resorption

    Ines Glojnaric, Snjezana Cuzic, Boska Hrvacic, Vanesa Ivetic Tkalcevic, Miroslava Dominis Kramaric and Vesna Erakovic Haber, Fidelta Ltd., Zagreb, Croatia

    Background/Purpose: Matrix metalloproteinase 13 (MMP-13) is expressed by chondrocytes and synovial cells in human osteoarthritis and rheumatoid arthritis (RA) (Takaishi et al., 2008). Serum MMP-13…
  • Abstract Number: 1276 • 2013 ACR/ARHP Annual Meeting

    Immunologic Monitoring and Infectious Complications In Pediatric Rheumatology Patients Treated With Rituximab

    Alysha Taxter1, Kathleen E. Sullivan2 and Jon Burnham3, 1Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, 2Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, 3Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Rituximab is an anti-CD20 monoclonal antibody increasingly used in immunologic and malignant conditions to deplete B cells. Suppression of humoral immunity after rituximab exposure may…
  • Abstract Number: 1277 • 2013 ACR/ARHP Annual Meeting

    A Pilot Study Of Young Adults With Juvenile Dermatomyositis With Decreased Nailfold Capillary End Row Loops:  Brachial Artery Reactivity and Oxidized Lipids

    Lauren M. Pachman1,2, Maureen A. McMahon3, Tamar Polonsky4, Gabrielle A. Morgan1, Maria Amoruso5 and Chiang-Ching Huang6, 1Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, 2Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 4Cardiology, University of Chicago Medicine, Chicago, IL, 5Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Cure JM Myositis Center, Chicago, IL, 6Zilber School of Public Health, University of Wisconsin at Milwaukee, Milwaukee, WI

    Background/Purpose: Our center previously reported increased carotid intima media thickness, and lower high-density lipoprotein (HDL) levels in young or middle-age adults with a history of…
  • Abstract Number: 1278 • 2013 ACR/ARHP Annual Meeting

    The Arthritis Severity and Joint Damage Locus Cia25/Pia42 Is a New Genetic Regulator of the Invasive Properties of Synovial Fibroblasts

    Max Brenner1,2, Teresina Laragione1,2 and Percio Gulko1,2, 1Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 2Molecular Medicine, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic and commonly disabling disease with a prevalence of 1% world-wide. Disease remission is rarely achieved with current treatments…
  • Abstract Number: 1280 • 2013 ACR/ARHP Annual Meeting

    The Role of Sphingosine-1-Phosphate Receptor 3 Signaling in Murine Collagen-Induced Arthiritis

    Hidetake Nagahara1, Masataka Kohno1, Ken Murakami1, Aihiro Yamamoto1, Takahiro Seno1, Wataru Fujii1, Kazuki Fujioka1, Yuji Kukida1, Ryo Oda2, Hiroyoshi Fujiwara2 and Yutaka Kawahito1, 1Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 2Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, kyoto, Japan

    Background/Purpose: Sphingolipids represent a major class of lipids that are ubiquitously expressed in eukaryotic cell membranes. Through the interaction with a family of five G-protein-coupled…
  • Abstract Number: 1281 • 2013 ACR/ARHP Annual Meeting

    Inadequate Glucocorticoid Secretion in Experimental Arthritis in Rats Is Closely Linked to Impaired Mitochondria and Reduced Lipid Breakdown in the Adrenal Cortex

    Christine Wolff1, Katharina Krinner1, Josef Schröder2 and Rainer H. Straub3, 1Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, Department of Internal Medicine I, University Hospital, Regensburg, Germany, 2Department of Phatology, University Hospital, Regensburg, Germany, 3Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany

    Background/Purpose: In rheumatoid arthritis a functional deterioration of the HPA-axis in form of inadequately low secretion of glucocorticoids in relation to severity of inflammation can…
  • Abstract Number: 1282 • 2013 ACR/ARHP Annual Meeting

    Effect of RC-3095, An Antagonist of Gastrin-Releasin Peptide Receptor, Regulating Synovial Fibroblasts in Experimental Arthritis

    Patricia Oliveira1, Lidiane Filippin2, Mirian Farinon2, Vanessa Clarimundo2, Gilberto Schwartsmann2 and Ricardo M. Xavier3, 1Rheumatology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, 2Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Rheumatology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

    Background/Purpose: The gastrin-releasing peptide (GRP) is the mammalian homologue of the bombesin (BN), and its receptor signaling is involved in several functions, including inflammatory response.…
  • Abstract Number: 1283 • 2013 ACR/ARHP Annual Meeting

    Power Doppler Ultrasound Phenotyping of Expanding Versus Collapsed Popliteal Lymph Nodes in Murine Inflammatory Arthritis

    Echoe M. Bouta1, Yawen Ju2, Homaira Rahimi3, Ronald Wood4, Lianping Xing5 and Edward M. Schwarz6, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY, 3Pediatrics, University of Rochester, Rochester, NY, 4Department of Urology, University of Rochester Medical Center, Rochester, NY, 5Pathology & Lab Medicine, University of Rochester, Rochester, NY, 6Center for Musculoskeletal Research, University of Rochester, Rochester, NY

    Background/Purpose:   Rheumatoid arthritis is a chronic inflammatory disease manifested by episodic flares in affected joints that are challenging to predict and treat.  Longitudinal contrast…
  • « Previous Page
  • 1
  • …
  • 2342
  • 2343
  • 2344
  • 2345
  • 2346
  • …
  • 2605
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology